Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers

NCT04679493 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Covid19
Healthy Volunteers

Interventions

DRUG: XC7 100 mg single
DRUG: XC7 200 mg single
DRUG: Placebo single
DRUG: XC7 200 mg multiple
DRUG: Placebo multiple

Sponsor

NP Therapeutics